COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Multicenter, Open-Label, Dose-Escalation Phase 1b Study Of AEVI-007 In Subjects With Relapsed Or Refractory Multiple Myeloma

Protocol No
AEVI-007-MM-101
Principal Investigator
Parameswaran Hari
Phase
I
Summary
AEVI-007 is a human monoclonal antibody that functions by affecting human interleukin (IL)-18. Interleukins are naturally occurring proteins that handle communication between cells, regulate cell growth, and manage differentiation to other cells in your body, and cell movement. Generally, levels of IL-18 are increased in patients with multiple myeloma and is associated with decreased survival of patients.
Description
AEVI-007,in the treatment of relapsed or refractory multiple myeloma.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL